CBD Provider NuLeaf Naturals Appears before FDA in Support of Industry Regulation and Standards
DENVER, June 6, 2019 /PRNewswire/ — On May 31, NuLeaf Naturals representative Crystal Guess was one of 140 individuals to testify in a groundbreaking public meeting called by the Food and Drug Administration (FDA). In light of the 2018 Farm Bill, which...
Why Cronos’ (CRON) Entry Into U.S. CBD Market Could Be Overrated Over the Long Term
Cronos Group (CRON) got a nice boost from its upgrade from Underperform to Buy from Bank of America/Merrill Lynch analyst Christopher Carey, who also boosted his price target on the company from $13.00 to $20.00 per share. The impetus behind upgrading the stock by two...
REPEAT – International Cannabis Acquires Exclusive International Rights to Self-Dispensing THC/CBD Vending Machine Canadian Stock Exchange:WRLD-U.CN
(MENAFN – GlobeNewsWire – Nasdaq) itemprop=”articleBody”>VANCOUVER, British Columbia, June06, 2019(GLOBE NEWSWIRE) — ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (“ICC” or ‘International...
REPEAT – International Cannabis Acquires Exclusive International Rights to Self-Dispensing THC/CBD Vending Machine
VANCOUVER, British Columbia, June 06, 2019 (GLOBE NEWSWIRE) — ICC International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC:WLDCF) (“ICC” or “International Cannabis” or the “Company”) is pleased to announce the Company has...
Cronos catapults higher after saying it plans to enter the US CBD market within the next year (CRON)
Associated Press Cronos Group CEO Mike Gorenstein on Tuesday said the company would expand to the US within the next year. Bank of America Merrill Lynch upgraded the stock to “buy” from “underperform.” Shares were up more than 15%....
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Leading CBD Pet Line Mary’s Tails Now Available at PetSmart
DENVER, May 13, 2020 /PRNewswire/ — Pet parents seeking trustworthy hemp-derived cannabidiol (CBD) solutions for their dogs and cats can now find leading hemp extract brand, Mary’s Tails, in select PetSmart stores throughout the country....
Vext Science, Inc. Grants Stock Options
VANCOUVER , May 12, 2020 /CNW/ – Vext Science, Inc. (“VEXT” or the “Company“) (OTCQX: VEXTF; CSE: VEXT) is pleased to announce that it has granted 1,083,334 stock options at an exercise price of CAD$0.75 to directors, officer, and...
Cannabis Testing Lab Says CBD Co. Falsified Results
Law360 (May 12, 2020, 1:52 PM EDT) — Wisconsin cannabis testing lab Accelerated Analytics has accused a CBD manufacturer of falsifying its lab reports to conceal illegal concentrations of THC in its products and overstate their cannabinoid content. Lifted...
PURA Pursues $8.5 Billion Sun Care Market Entry With CBD Infused Products
PURA targets CBD product acquisitions that can be enhanced with PURA’s patented technology. PURA owns a license to a U.S. Patented cannabis extraction process backed by extensive university medical research. The license, issued by NCM Biotech, is exclusive for...
Why Colombia Poses a Threat to Cannabis Stocks
Popular cannabis stocks including Canadian giants Canopy Growth Corp. (CGC), Tilray Inc. (TLRY) and Aurora Cannabis (ACB) – the poster companies of the marijuana wave – now face an emerging threat as North American pot growers start to move their farms to...
A Sign of Trouble Ahead for Canopy Growth (CGC) Stock
Public Hearing On Friday, the FDA held a public hearing to discuss the safety of the cannabis product for human use. Commissioner Ned Sharpless made this comment that sent the industry stocks substantially lower on the day: “When hemp was removed as a controlled...
FDA Hearing Won’t Hurt Canopy’s Growth, But It Could Hit CGC Stock
Like many cannabis stocks, Canopy Growth (NYSE:CGC) fell in Monday trading due to an FDA meeting on CBD. Marijuana stocks fell as speakers at this inquiry offered conflicting views of the marijuana industry. Although the hearing will likely not stop the march toward...
Here’s What Last Week’s FDA CBD Hearing Really Means for Cannabis Stocks
Ten hours of testimony, more than 100 individuals speaking, and still a lot of unanswered questions. That’s the quick overview of the public hearing held by the U.S. Food and Drug Administration (FDA) last Friday to get feedback on regulations for cannabidiol...
Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substance
Cannabis stocks were mostly lower Monday, as investors digested the first reports from Friday’s regulatory hearing on cannabis and its ingredients and the news that Illinois is legalizing weed for adult recreational use. The U.S. Food and Drug Administration conducted...
Recent Comments